These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 7856224)
1. Omega 3 fatty acids in renal diseases. De Caterina R World Rev Nutr Diet; 1994; 76():137-42. PubMed ID: 7856224 [No Abstract] [Full Text] [Related]
2. [Efficacy of omega-3 fatty acids on renal diseases: are they justified?]. Hernández D; García S; González A; Rufino M; Salido E; Torres A Nefrologia; 2005; 25(3):221-32. PubMed ID: 16053003 [No Abstract] [Full Text] [Related]
3. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Meyrier A Nephrol Dial Transplant; 1992; 7 Suppl 1():80-4. PubMed ID: 1337187 [No Abstract] [Full Text] [Related]
5. Use of mycophenolic acid in non-transplant renal diseases. Stassen PM; Kallenberg CG; Stegeman CA Nephrol Dial Transplant; 2007 Apr; 22(4):1013-9. PubMed ID: 17307748 [No Abstract] [Full Text] [Related]
6. Effect of a specific endothelin receptor A antagonist on murine lupus nephritis and IgA nephropathy. Ebihara I; Nakamura T; Tomino Y; Koide H Contrib Nephrol; 1996; 118():155-63. PubMed ID: 8744053 [No Abstract] [Full Text] [Related]
8. n-3 Fatty acids and their role in nephrologic practice. Donadio JV Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):639-42. PubMed ID: 11496058 [TBL] [Abstract][Full Text] [Related]
9. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Donadio JV Mayo Clin Proc; 1991 Oct; 66(10):1018-28. PubMed ID: 1921484 [TBL] [Abstract][Full Text] [Related]
10. The emerging role of omega-3 polyunsaturated fatty acids in the management of patients with IgA nephropathy. Donadio JV J Ren Nutr; 2001 Jul; 11(3):122-8. PubMed ID: 11466662 [TBL] [Abstract][Full Text] [Related]
12. n-3 fatty acids and renal diseases. De Caterina R; Endres S; Kristensen SD; Schmidt EB Am J Kidney Dis; 1994 Sep; 24(3):397-415. PubMed ID: 8079965 [TBL] [Abstract][Full Text] [Related]
13. [IgA nephropathy--advances of therapy]. Prokopiuk M; Wierzbicki P; Kade G Pol Arch Med Wewn; 2001 Nov; 106(5):1079-86. PubMed ID: 12026523 [No Abstract] [Full Text] [Related]
14. Cyclosporine treatment of glomerular diseases. Klein M; Radhakrishnan J; Appel G Annu Rev Med; 1999; 50():1-15. PubMed ID: 10073260 [TBL] [Abstract][Full Text] [Related]
15. Use of mycophenolate mofetil in autoimmune and renal diseases. Appel GB; Radhakrishnan J; Ginzler EM Transplantation; 2005 Oct; 80(2 Suppl):S265-71. PubMed ID: 16251859 [TBL] [Abstract][Full Text] [Related]
16. Interstitial inflammatory and chronic tubulointerstitial lesions in lupus nephritis: comparison with those in IgA nephropathy. Yamamoto T; Nagase M; Hishida A; Honda N Lupus; 1993 Aug; 2(4):261-8. PubMed ID: 8268975 [TBL] [Abstract][Full Text] [Related]
17. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Fassett RG; Gobe GC; Peake JM; Coombes JS Am J Kidney Dis; 2010 Oct; 56(4):728-42. PubMed ID: 20493605 [TBL] [Abstract][Full Text] [Related]
18. Biologics for the treatment of autoimmune renal diseases. Holdsworth SR; Gan PY; Kitching AR Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177 [TBL] [Abstract][Full Text] [Related]
19. Suppression of autoimmune disease by omega-3 fatty acids. Robinson DR; Knoell CT; Urakaze M; Huang R; Taki H; Sugiyama E; Xu LL; Yeh ET; Olesiak W; Guo M Biochem Soc Trans; 1995 May; 23(2):287-91. PubMed ID: 7672312 [No Abstract] [Full Text] [Related]
20. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Clark WF; Parbtani A Am J Kidney Dis; 1994 May; 23(5):644-7. PubMed ID: 8172205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]